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Abstract
Background: The tumor microenvironment contains normal, non-neoplastic cells that may contribute to tumor growth and
maintenance. Within PDGF-driven murine gliomas, tumor-associated astrocytes (TAAs) are a large component of the tumor
microenvironment. The function of non-neoplastic astrocytes in the glioma microenvironment has not been fully
elucidated; moreover, the differences between these astrocytes and normal astrocytes are unknown. We therefore sought
to identify genes and pathways that are increased in TAAs relative to normal astrocytes and also to determine whether
expression of these genes correlates with glioma behavior.
Methodology/Principal Findings: We compared the gene expression profiles of TAAs to normal astrocytes and found the
Antigen Presentation Pathway to be significantly increased in TAAs. We then identified a gene signature for glioblastoma
(GBM) TAAs and validated the expression of some of those genes within the tumor. We also show that TAAs are derived
from the non-tumor, stromal environment, in contrast to the Olig2+ tumor cells that constitute the neoplastic elements in
our model. Finally, we validate this GBM TAA signature in patients and show that a TAA-derived gene signature predicts
survival specifically in the human proneural subtype of glioma.
Conclusions/Significance: Our data identifies unique gene expression patterns between populations of TAAs and suggests
potential roles for stromal astrocytes within the glioma microenvironment. We show that certain stromal astrocytes in the
tumor microenvironment express a GBM-specific gene signature and that the majority of these stromal astrocyte genes can
predict survival in the human disease.
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Introduction
Gliomas are the most common primary malignant brain tumor
in adults [1]. Current treatment options for glioma include surgical
resection, radiation therapy and chemotherapy. Unfortunately,
even with these aggressive treatments, patient response is poor and
average survival of patients with aggressive forms of glioma is less
than 2 years [2]. One possible reason for poor patient response to
treatment may be that standard glioma therapy regimen do not
account for the effects of stromal cells within the tumor
microenvironment [3]. There is a lack of stroma-directed therapy
due to the paucity of data clarifying the role of local non-
transformed cells in glioma maintenance and progression. As the
role of the tumor microenvironment becomes increasingly relevant
it is important to identify stromal cells and factors that may
contribute to tumor growth.
Recent advances in characterizing gene expression profiles from
patient samples have divided gliomas into four main subgroups
(Classical, Mesenchymal, Neural and Proneural) each highlighted
by the activation or loss of specific signaling pathways [4–6].
Notable genetic alterations in high-grade gliomas include loss of
NF1, increased EGFR signaling and increased PDGF signaling
[5]. The Proneural subgroup of gliomas, which is characterized by
increased PDGF signaling [5,7], can be effectively modeled using
the RCAS/tv-a system of retroviral gene transfer of PDGF into
Nestin-expressing cells in neonatal mouse brains [8,9]. This
genetically engineered tumor model recapitulates the biology of
human gliomas in an immunocompetent host, allowing for the
study of transformed cells as well as stromal cells in the tumor
microenvironment. In this PDGF-induced model of glioma,
tumors of varying grades arise and can be characterized in a
histologically accurate manner. Low-grade gliomas exhibit prolif-
eration of tumor cells surrounded by a relatively quiescent stromal
architecture (WHO grade II), whereas high-grade tumors are
histologically similar to WHO grade III and IV and feature
proliferating cells in addition to marked microvascular prolifera-
tion (Grades III and IV) and pseudopalisading necrosis (Grade
IV). In the PDGF-driven model of glioma, the tumor bulk is
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microenvironment contains many cell types that may contribute to
tumor growth and maintenance. Among these cells, astrocytes are
relatively abundant in the tumor microenvironment and may
contribute to tumor growth. While the histology of TAAs has been
described [10], the biological role of these astrocytes is largely
unexplored.
Astrocytes are often identified by their expression of Glial
Fibrillary Acidic Protein (GFAP), which increases in response to
injury. Astrocytes were originally thought to play a passive role in
the brain, but they are now known to play critical roles in
supporting the integrity of the blood brain barrier [11] and the
transmission of neural impulses [12]. In addition, astrocytes
contribute to the brain’s response to injury. When injury occurs,
astrocytes become reactive, change their morphology, proliferate
and migrate to the area of injury. Depending on the context of
injury, they may promote and/or inhibit neurogenesis [13,14].
Recently, our group found that reactive astrocytes can induce
proliferation of Olig2-expressing cells after injury [15]. This
finding raises the intriguing possibility that astrocytes may be
associated with expanding oligodendrocyte cell populations in
other central nervous system disease states, including neoplasms.
In addition to reactive astrocytes, adult neural stem cells (aNSC)
also express GFAP [16]. These cells share ultrastructural and
protein expression characteristics with mature astrocytes [17] and
reside in two neurogenic niches within the adult brain: the sub-
ventricular zone of the lateral ventricles and the sub-granular zone
in the dentate gyrus of the hippocampus [18]. Within these
regions, the neural stem cells reside adjacent to blood vessels
[19,20] and these adult astrocyte-like stem cells proliferate slowly
and are thought to divide asymmetrically [21] to give rise to
progenitor cells that proliferate rapidly and symmetrically to
produce terminal cell types such as neurons [22–24] and glia
[23,25].
Recent studies have highlighted the plasticity of astrocytes with
regard to their functions in injury and as stem cells. In addition to
shared markers and ultrastructural characteristics between reactive
astrocytes and aNSC, recent work has demonstrated that reactive
astrocytes derived from an injury setting possess characteristics
specific to aNSC, including the expression of aNSC markers as
well as the ability to proliferate and generate neurospheres
[11,14,26,27]. These studies suggest a novel role for astrocytes in
the context of injury and demonstrate the plasticity of reactive
astrocytes.
The role of astrocytes can vary significantly among gliomas. In
PDGF-driven gliomas where the majority of transformed cells
closely resemble oligodendrocytes, astrocytes appear to play a
supportive role in the perivascular stem cell niche and the peri-
tumoral (invasive) edge of these tumors. In contrast, the bulk of the
tumor cells in astrocytomas are astrocytic in morphology. The
biology of transformed astrocytes derived from astrocytomas,
including the genetic alterations and gene expression patterns in
these cells, has been studied in depth. However, little is known
about the TAAs found in PDGF-driven oligodendrogliomas.
Considering the growth-promoting and stem cell properties of
astrocytic cells in normal physiologic states and brain injuries and
the possibility that these properties can be co-opted by the tumor
to promote proliferation and progression, we were compelled to
study the gene-expression properties of TAAs in PDGF-driven
gliomas with the goal of identifying stromal factors that contribute
to tumorigenesis.
To study TAAs, we used a GFAP-GFP transgenic mouse that
expresses GFP under the control of the human GFAP promoter,
which allows for isolation of astrocytes using fluorescence activated
cell sorting (FACS) from normal and tumor brains. When
compared to normal astrocytes, samples enriched for TAAs show
markedly increased expression of members of the antigen
presentation pathway. Additionally, we identified genes specific
to TAAs in GBM and validate their expression. We also
demonstrate that TAAs are derived from the stromal microenvi-
ronment and that many of the gene expression changes seen in
TAAs are specifically present in stroma and not in tumor cells.
Further, we demonstrate that many of these differentially
expressed genes predict survival in the human proneural subtype
of glioma. These data suggest a role for stromal astrocyte-
expressed genes in tumor progression and identifies potential
therapeutic targets in the treatment of proneural gliomas.
Results
Tumor-associated Astrocytes are a Component of the
Glioma Microenvironment
To generate tumors that mimic the proneural subtype of
glioma, we injected the RCAS-PDGF avian retrovirus into Ink4a/
Arf heterozygous mice that express the RCAS receptor tv-a under
the control of the Nestin promoter. Using this model, Ink4a/Arf
heterozygous mice injected with RCAS-PDGF develop tumors of
varying grades within four to eight weeks. Upon manifestation of
brain tumor symptoms such as weight loss and poor grooming,
mice were sacrificed and their brains were fixed and embedded in
paraffin for histologic analysis and grading. Using RCAS-PDGF in
the Ink4a/Arf heterozygous background allows for the generation
of tumors of varying grades within the same litter (Figure S1A).
As described above, the tumor bulk in the PDGF-driven model
of glioma expresses Olig2, while the GFAP-expressing cells are
part of the tumor stroma. These stromal astrocytes are
geographically and morphologically different from normal astro-
cytes (Figure 1A). In low-grade gliomas, the astrocytes are present
throughout the tumor in a diffuse pattern (Figure 1B). These
astrocytes are morphologically similar to reactive astrocytes, with
swollen cell bodies and processes extending in multiple directions
(Figure 1B). In the PDGF-induced GBMs, astrocytes are present in
the tumor in two distinct areas: the peri-tumoral region, located at
the tumor periphery, and the perivascular niche which is
hypothesized to harbor the stem cell niche in glioblastoma [28]
(Figure 1C). The peri-tumoral astrocytes have swollen cell bodies
and processes that extend out in multiple directions (Figure 1B9,
1C9). This population of astrocytes surrounds the tumor in a
manner similar to the way in which reactive astrocytes surround
an area of injury [11] and this population of astrocytes is present in
tumors of all grades (Figure 1B,1C). The perivascular astrocytes,
however, are only present at a significant level in high-grade
glioma, where significant microvascular proliferation is present
[29]. We also noted that these astrocytes have a more bipolar
morphology [24] (Figure 1C0) and are localized to areas
surrounding the tumor blood vessels (Figure 1C, Figure S1B)
[19,20]. The perivascular astrocytes also express the stem cell
marker Nestin [10].
The mRNA Profile of Tumor-associated Astrocytes Differs
from Normal Astrocytes
In order to determine the differences between normal astrocytes
and TAAs and to identify genes and pathways increased in TAAs
we generated PDGF-driven gliomas in GFAP-GFP transgenic
mice, which express GFP under the control of the human GFAP
promoter [30], and used FACS to specifically collect samples
enriched for TAAs from microdissected low-grade gliomas and
GBM. We used FACS and histology to confirm that the GFP-
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cells (Figure S2A–D). Normal astrocytes were collected from 6
week-old mice that were not injected with the RCAS virus.
Collected astrocytes were resuspended in trizol, their RNA was
extracted and cDNA was run on illumina-6 arrays and Partek
software was used to analyze samples. Unbiased hierarchical
clustering analysis of all genes significantly represented on the
array showed that TAAs exhibit similar expression patterns
regardless of tumor grade, indicating a shared phenotype, and
that TAAs differ markedly from normal astrocytes (Figure 1D).
MHC Class II Pathway Is Active In Tumor-associated
Astrocytes
In order to identify genes and pathways significantly changed in
TAAs, we generated a list of genes that were increased or
decreased by four-fold in both low-grade glioma and GBM TAAs
relative to normal astrocytes. We specifically characterized low-
grade tumors as WHO grade II tumors (lacking vascular
proliferation) and GBM as tumors exhibiting both hypervascular-
ity and pseudo-pallisading necrosis (WHO grade IV). We then
used ingenuity pathway analysis (IPA) to query pathways
associated with the resulting genes and identified the antigen
presentation pathway as the most significantly represented
pathway increased in TAAs relative to normal astrocytes
(Table 1). While previously published data has shown astrocytes
to have antigen-presenting capabilities in vitro as well as in in vivo
injury models [31–35], this function of stromal astrocytes has not
Figure 1. Tumor-associated Astrocytes within PDGF-driven Glioma. (A–C) GFAP immunohistochemistry of astrocytes in the normal brain (A,
A9), WHO II low-grade glioma (B, B9) and glioblastoma (GBM; C, C9,C 0)a t1 6(A, B, C) and 406(A9,B 9,C 9,C 0). Note that tumor-associated astrocytes
(TAAs) are morphologically different than normal astrocytes. Moreover, in low grade glioma, TAAs are present within and surrounding the tumor and
all of these astrocytes have a ‘reactive’ morphology identified by swollen cell bodies as well as multipolar and hyperextended processes (B9). Within
GBM (C), astrocytes are present in two areas: the peri-tumoral area, where the astrocytes have a ‘reactive’ morphology (C9) similar to low grade
astrocytes and the perivascular niche, where the astrocytes still have swollen cell bodies but have a more uni-polar or bi-polar morphology (C0). Scale
bars: A, B, C=300 mm, A9,B 9,C 9,C 0=15mm. D) Unbiased hierarchical clustering of astrocytes from normal brain, low-grade glioma and GBM indicates
that, when factoring in the mRNA expression levels of approximately 15,000 genes significantly expressed on the array, TAAs are very different from
normal astrocytes, however most genes are similarly regulated between low grade-associated and GBM-associated astrocytes and thus, low grade-
associated and GBM-associated astrocytes do not segregate.
doi:10.1371/journal.pone.0032453.g001
Table 1. Antigen Presentation Pathway is Active in Tumor-
associated Astrocytes.
Ingenuity Canonical Pathways -log(p-value) Ratio
Antigen Presentation Pathway 1.08E+01 2.56E-01
Dendritic Cell Maturation 7.81E+00 8.05E-02
Type I Diabetes Mellitus Signaling 6.05E+00 8.70E-02
Crosstalk between Dendritic Cells and
Natural Killer Cells
5.55E+00 9.18E-02
Virus Entry via Endocytic Pathways 4.65E+00 8.33E-02
Caveolar-mediated Endocytosis Signaling 4.30E+00 8.43E-02
B Cell Development 4.00E+00 1.32E-01
CXCR4 Signaling 3.70E+00 5.39E-02
Allograft Rejection Signaling 3.69E+00 1.11E-01
Graft-versus-Host Disease Signaling 3.69E+00 1.11E-01
 2000–2010 Ingenuity Systems, Inc. All rights reserved.
Ingenuity Pathway Analysis of genes significantly increased more than four-fold
in low-grade glioma- and glioblastoma-associated astrocytes indicates the
pathways that are significantly increased in TAAs relative to normal astrocytes.
The top ten canonical pathways represented on the array are shown in the
table. The Antigen Presentation Pathway is most represented within this gene
set.
doi:10.1371/journal.pone.0032453.t001
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flourescent staining to confirm MHC class II expression on TAAs
in low-grade gliomas and GBM (Figure S3A) and stained with Iba-
1, an immune cell marker, to demonstrate that these MHC class
II-expressing astrocytes were not microglia or macrophages. We
also used FACS analysis to demonstrate an increase in MHCII
expression on TAAs when compared to normal astrocytes (Figure
S3B,C). In addition to MHC class II, our array analysis identified
other components of antigen presentation pathway as being
increased in TAAs (Table S1).
Comparative Expression Identifies a Stromal Gene
Signature for GBM Tumor-associated Astrocytes
In order to identify stromal genes important for tumorigenesis,
we next looked specifically for genes expressed at much higher
levels in GBM TAAs when compared to TAAs from low-grade
gliomas. Having established that the astrocytes from low-grade
glioma and GBM were relatively similar, we hypothesized that
there may be a subset of genes differentially expressed between the
two populations and that these genes may play a role in tumor
progression. In order to identify genes specific to GBM TAAs we
plotted gene expression data in TAAs from low-grade gliomas and
compared it to that of TAAs from GBMs (Figure 2A). Since the
perivascular niche is only present in GBM [29], high-grade
gliomas would be expected to have a more robust representation
of perivascular astrocytes and thus some differentially expressed
genes in GBM TAAs may represent genes specific to the
perivascular astrocytes. Our data show that the mRNA expression
profiles in TAAs are relatively similar regardless of grade
(Figure 1D, Figure 2A), however, a small subset of GBM-specific,
astrocyte-associated genes emerged from this analysis (Figure 2A,
Table 2). In fact, using this gene signature in hierarchical
clustering analysis enabled us to differentiate GBM gene
expression from low-grade glioma (Figure 2B). We screened a
number of antibodies to these GBM-specific genes using
immunofluorescence and chose two (Tenascin C and CD44) for
further analysis. CD44 and Tenascin C show clear expression in
astrocytes (Figure 2C,D). Moreover, their expression is virtually
restricted to perivascular astrocytes. We also noted that CD44, a
known stem cell marker [36,37], is only expressed in specific
astrocytes within the perivascular niche (Figure S4A) as well as in
GFAP-expressing neurospheres (Figure S4B). However, CD44
does not stain astrocytes that reside further from the ventricle
(Figure S4A) or cultured, differentiated astrocytes (Figure S4B,C).
Tumor-associated Astrocytes Are Frequently Derived
From the Stromal Environment
Because astrocytes are an abundant component of the tumor
microenvironment, we asked whether TAAs were derived from
the RCAS-transduced tumor cell of origin or from the stromal
microenvironment. To achieve this goal, we utilized fluorescently
labeled RCAS-PDGF vectors combined with immunofluorescence
and FACS analysis. We generated gliomas using RCAS-PDGF-
GFP [10,38]. We then used GFP immunofluorescence to identify
tumor progeny cells and stained the same tissue for GFAP to
identify astrocytes and look for co-localization. In these PDGF-
driven gliomas, PDGF-GFP infected tumor cells and GFAP-
expressing astrocytes were expressed in mutually exclusive areas
(Figure 3A), confirming that the astrocytes in our tumors are
stromal. We validated this data using a model of human orthotopic
glioma injected into GFAP-GFP host mice. In this orthotopic
model, TAAs derived from tumor cells would not express the
GFAP-GFP transgene; conversely, TAAs derived from non-tumor
cells should express GFP. When we injected non-fluorescent
human tumorspheres into GFAP-GFP host mice, we noted robust
correlation of GFP and GFAP expression, consistent with the
hypothesis that these TAAs are host derived. (Figure 3B). While
the orthotopic tumors exhibited a smaller degree of microvascular
proliferation than mouse tumors, all perivascular areas within the
tumors contained host-derived, GFP+, GFAP-expressing cells.
Importantly, this finding implies that host derived TAAs are
present in the tumor stem cell niche.
Since GFAP-expressing cells have extensive processes with
indistinct boundaries, immunostaining may not always be the ideal
way to differentiate host-derived astrocytes from astrocytes that are
derived from injected tumors. We therefore used FACS analysis to
determine whether GFAP-expressing cells were derived from
tumor cells or the non-neoplastic microenvironment. For these
experiments we used an RCAS-PDGF-mRFP virus to generate
tumors in GFAP-GFP [30] and Olig2-rpGFP mice [39]. Analysis
of tumors generated in Olig2-rpGFP mice infected with RCAS-
PDGF-RFP showed that most of the PDGF-RFP infected cells
were Olig2-expressing cells, consistent with the idea of an
oligodendrocyte lineage in tumor cells derived by PDGF over-
expression (Figure 3C). Correspondingly, tumors generated by
injecting RCAS-PDGF-mRFP into GFAP-GFP transgenic mice,
showed little to no expression of PDGF-RFP within the GFAP-
GFP population (Figure 3D). It is worth noting that a large
percentage of PDGF-RFP infected cells expressed low levels of
GFP and, given our staining and FACS data, these represent
PDGF-infected Olig2+ tumor cells that also express low levels of
GFAP [40] (Figure 3A, C). Finally, as a first step toward exploring
the biological properties of these stromal TAAs, we assessed their
ability to generate neurospheres in vitro and found that they
generated neurospheres under the appropriate conditions (Figure
S4D). This property is reminiscent of injury-associated reactive
astrocytes, which also display neurosphere-generating capacity
[14].
Expression Levels of GBM-associated Astrocytic Stromal
Genes Predict Survival in Human Proneural GBMs
Specifically
We next sought additional confirmation that GBM TAAs genes
were expressed in the stromal compartment of the tumor
microenvironment and not in the tumor cells. To do this, we
plotted the gene expression data from whole tumors relative to the
gene expression data from the Olig2-expressing tumor cells that
had been sorted from the rest of the tumor. This analysis enables
us to identify genes specific to stromal cells, as these genes would
only be expressed in the whole tumor population and not in the
purified Olig2+ tumor cell population. Using this analysis, most of
the genes identified as specific to GBM TAAs when compared to
low grade (WHO Grade II) TAAs were also identified as arising
only in the stromal compartment of the tumor and not in the
Olig2-expressing tumor cells (Figure 4A). In fact, of the 38 genes
identified, only 3 genes (8%) were expressed at higher levels in the
tumor cells, whereas 24 genes (63%) were expressed at significantly
higher levels in whole tumor relative to Olig2 tumors cells and 11
genes (29%) did not demonstrate a significant expression
difference between Olig2 cells and whole tumors. Taken together,
these data confirm that genes expressed in GBM TAAs are
expressed predominately in the stromal microenvironment rather
than in the Olig2-expressing tumor cells.
Once we confirmed the stromal nature of the GBM TAAs
signature genes, we were interested in knowing whether these
stromal genes play a role in tumorigenesis. Moreover, given the
differences in the astrocytic component of proneural gliomas
Tumor-Associated Astrocytes in PDGF-Driven Glioma
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32453Figure 2. A Gene Signature for GBM Astrocytes. A) Dot-plot of the expression levels of all genes significantly expressed in low-grade-associated
astrocytes and GBM-associated astrocytes. Red lines demarcate genes similarly expressed regardless of grade and dots outside the red lines represent
genes expressed at higher levels in GBM-associated astrocytes. Red arrows point to the dots representing Cd44 and Tenascin C. B) Hierarchical
clustering of the genes off the plot that are expressed at a higher level in GBM-associated astrocytes relative to low-grade-associated astrocytes
Tumor-Associated Astrocytes in PDGF-Driven Glioma
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32453compared to non-proneural tumors, we were interested in
exploring the possibility that proneural TAAs play a role in the
molecular pathophysiology of proneural glioma. In order to
understand whether our GBM TAA signature is active in human
tumors, we turned to the TCGA dataset [6] and asked whether
expression of these genes can predict survival in any given tumor
subtype. For each gene, patients were divided into two groups, low
expressing and high expressing, based on the median expression of
a given gene within a given subtype. For all four subtypes of
glioma, we determined the average survival of patients based on
their expression levels of each gene and plotted the difference in
survival between low and high expressing patients (Figure 4B,
Figure S5). In the proneural subtype, 17 of the 38 genes (45%)
showed a significant, inverse correlation with survival, where high
expression was associated with worse prognosis. Further, of these
17 genes, 12 of them are associated with a significant survival
difference of more than 6 months and of those, 10 genes predict a
significant survival difference of more than 1 year. Additionally, 8
of the 12 genes that predict a difference in survival of more than 6
months are enriched in the stromal compartment. Notably, most
of these genes did not significantly correlate with survival in the
Classical, Mesenchymal or Neural subtypes of glioma. In addition,
neither GFAP nor FGF3, two established astrocyte markers
[11,41] are associated with survival, indicating that these
correlations are specific to gene expression, rather than a simple
indication of astrocyte density present in the tumor microenvi-
ronment. These data indicate that stromal astrocyte gene
expression patterns within the proneural subtype of glioma
correlate with patient outcome and may serve as useful biomarkers
for the proneural subtype of glioma.
Recent data has identified the presence of a CpG island
methylator phenotype (CIMP) within the Proneural subgroup
[42]. These tumors have hypermethylated promoter CpG islands,
which results in transcriptional silencing of the associated genes.
The glioma-CIMP (G-CIMP) tumors have a more favorable
prognosis when compared to non-CIMP Proneural tumors or
gliomas within the Classical, Mesenchymal and Neural subtypes.
We therefore explored whether the CIMP phenotype altered the
prognostic potential of our GBM TAAs signature genes.
Remarkably, we found that the GBM TAAs signature genes can
only predict survival in the Proneural subtype when the G-CIMP
samples are included, and not when the G-CIMP samples are
excluded from the data set (Figure 4B, Figure S5). In fact, while
expression of these genes is low in the Proneural subtype in
general, it is even lower in the G-CIMP tumors (Figure S6),
indicating a connection between these genes or stromal astrocytes
and G-CIMP tumors.
Discussion
Our understanding of astrocyte function in neurological disease
has increased vastly in recent years. Whereas astrocytes were once
thought to be post-mitotic, negative regulators of tissue growth, we
now know that astrocytes possess proliferative and progenitor cell
functions [14,15]. The majority of the data on astrocyte function
comes from injury models, neurodegenerative disorders, trans-
formed astrocytes in glial tumors, and the study of a small subset of
astrocyte-like adult neural stem cells. In this study, we identify
some basic characteristics of stromal astrocytes within the PDGF-
driven tumor microenvironment. Furthermore, we identify TAA
markers that are associated with survival in the human proneural
subtype of glioma.
Astrocytes respond to injury by changing their morphology,
proliferating and migrating to the site of injury [11]. Here we show
that in our PDGF-driven model of proneural gliomas, astrocytes
respond to tumors in a manner reminiscent of their response in
brain injury. TAAs surrounding the tumor are morphologically
‘reactive’ with swollen cell bodies, hyperextended processes
extending in multiple directions, and they express high levels of
GFAP. In an injury model, these astrocytes are capable of
inducing proliferation of Olig2-expressing cells [15] and it is
possible that this pro-proliferative astrocyte function may be
directed to Olig2-expressing tumor cells in proneural gliomas.
TAAs are not only structurally similar to injury-response
astrocytes but are also similar on a molecular level. Specifically,
they are thought to express Sonic Hedgehog [10,15] as well as
members of the antigen presentation pathway. The antigen
presentation pathway is mainly comprised of MHC class I and
class II molecules. These molecules are important for antigen
presentation to T cells. While previously published data has shown
that astrocytes possess antigen-presenting capabilities ex vivo and in
models of brain injury [31–35], this function of astrocytes has not
been identified in a glioma mouse model and highlights a novel
and potentially important role for TAAs.
In addition to the antigen presentation pathway, we also
identified a gene signature that distinguishes GBM-associated
astrocytes from those in lower grade gliomas. These genes are
mainly expressed in the stromal compartment of the tumor, and are
associated with survival in the proneural subtype of human glioma.
Two of these markers, CD44 and Tenascin C, which are expressed
in the stem cell niches of normal brains [37,43–45], are expressed at
much higher levels in the perivascular niche where tumor stem cells
are proposed to reside [28]. Additionally, the fact that CD44 and
Tenascin C are expressed at much higher levels in the perivascular
astrocytes when compared to peritumoral astrocytes suggests subtle
differences between the two populations of non-neoplastic tumor
astrocytes. We will direct some of our future studies towards
understanding whether these gene expression changes produces
functional differences in tumor pathophysiology.
To further understand characteristics of peritumoral and
perivascular TAAs, we investigated whether these cells were
derived from transformed cells, stroma, or both cellular compart-
ments. We expected to find that peritumoral astrocytes were
stromal in origin, but were intrigued to learn that perivascular
astrocytes found in the center of these tumors were also stromal in
origin. While it is tempting to attribute functional roles to these
astrocytes that exist at the core of the tumor stem cell niche, more
investigation is necessary before such conclusion can be reached.
It is not currently known where the stromal-derived perivascular
astrocytes originate. Numerous studies have shown that normal
neuralstem cells demonstrate a tropism towards tumors[46,47]and
the migration of normal neural stem cells out of the SVZ and SGZ
and into the tumor perivascular niche is a possibility. Another
explanation is that these perivascular astrocytes are simply local
astrocytes that become ‘‘trapped’’ within the perivascular niche. A
corollary to the latter hypothesis is that the presence of secreted
indicates that these genes are able to segregate GBM-associated astrocytes from low grade-associated astrocytes. C,D) Validation of CD44 (C) and
Tenascin-C (TNC; D) expression at low- and high-magnification. CD44 and TNC are expressed at high levels in perivascular astrocytes but expressed at
lower levels or not expressed at all in peri-tumoral astrocytes. Arrows point to perivascular astrocytes and arrowheads point to peri-tumoral
astrocytes. Scale bars=100 mm, 10 mm.
doi:10.1371/journal.pone.0032453.g002
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assume a more stem/progenitor phenotype and dedifferentiate.
This hypothesis is supported by previous work has shown that
reactive astrocytes are capable of stem-like behavior [14].
In addition to identifying stromal genes expressed in TAAs of
the PDGF-driven mouse gliomas, we identified that a subset of
these stromal genes are prognostic of survival in the human
proneural GBMs, where high expression was associated with
worse outcome. In fact, almost half of the genes identified were
able to predict a difference in survival of at least 1 year. Moreover,
the predictive value of these genes is specific to the proneural
subtype of glioma, indicating the possibility of a TAA effect within
the proneural subtype of human glioma. Interestingly, the
predictive value of these genes was lost when the g-CIMP patients
were removed. Three of the stromal genes (Rbp1, Lgals3 and
Anxa2) were methylated at a significantly higher level in g-CIMP
tumors compared to non-CIMP tumors [42], and even unmethy-
lated genes were significantly downregulated in g-CIMP tumors
when compared to non-CIMP tumors [42]. The association of
these genes with the g-CIMP tumors suggests the possibility of an
altered tumor microenvironment in the g-CIMP proneural tumors
when compared to the non-CIMP tumors. Further, that these
genes were identified within the stromal compartment raises the
question of the effects of the g-CIMP tumor cells on the non-
neoplastic stromal cells within the tumor.
Our data highlight the importance of the tumor microenviron-
ment, specifically TAAs, in the proneural subtype of glioma. These
TAAs respond to the tumor in the microenvironment and express
genes that are associated with overall patient survival. As more is
learned about the various pathways driving the neoplastic growth
of gliomas, we must also consider the role of the stromal cells
within these tumors. If these cells are capable of promoting tumor
growth, they may need to be targeted in treatment protocols.
Because these cells are not neoplastic, conventional mutagenic
treatments may not be effective and thus, the ability to target
specific growth-promoting pathways in these cells is imperative. It
will be important to identify other genes and pathways active in
stromal cells, but the identification of the antigen presentation
pathway as well as GBM TAAs signature genes provides us with a
starting point in elucidating the functional roles of tumor
microenvironment in progression and malignancy.
Methods
Generation of brain tumors
Nestin-tv-a (N-tva) transgenic mice were injected with DF1 cells
(purchased from ATCC) producing RCAS-PDGFB [8], RCAS-
PDGF-sv40-GFP [10] or RCAS-PDGF-RFP [48] as previously
described [10]. Mice were monitored carefully for symptoms of
tumor development (lethargy, hydrocephalus, head tilting). GFAP-
GFP mice were purchased from Jackson Laboratories and crossed
onto the Ntv-a, Ink4a/Arf null background to generate tumors that
Table 2. A Small Group of Genes are Expressed Only in GBM-
associated Astrocytes.
Gene Symbol
Fold-Change in GBM-associated vs. Low
grade-associated Astrocytes
Spp1 7.38667
Mmp10 5.59439
Serpina3h 4.74814
Col6a1 4.74803
Cd44 4.52953
Ctgf 4.33288
Col6a3 4.32895
Vgf 4.28414
Ctgf 4.27893
Lyz 4.23631
S100a11 4.13884
Mglap 4.13362
Aldh1a3 4.03689
Timp1 3.95154
Cd44 3.90811
Timp1 3.89863
Lyzs 3.86976
Emp1 3.82806
Col6a1 3.69735
Lcn2 3.57219
Igfbp7 3.47077
Sphk1 3.45682
Prss19 3.36531
Nupr1 3.31251
Col18a1 3.27824
C1qb 3.27781
Lgals3 3.2697
Anxa2 3.15955
Lyzs 3.10612
Hk2 3.06335
Arhgdib 3.00618
Tnc 2.99419
9130006A14Rik 2.98302
Tnc 2.97213
Ppic 2.89373
Ccl4 2.8926
Bgn 2.88815
C1qg 2.88698
Aldh1a3 2.85672
9230117N10Rik 2.85186
0610041G09Rik 2.83913
Lgals1 2.8309
Rbp1 2.81274
Anxa3 2.787
Table 2. Cont.
Gene Symbol
Fold-Change in GBM-associated vs. Low
grade-associated Astrocytes
Col18a1 2.75882
Dlk1 2.71719
Cd109 2.70004
Cdkn1a 2.69406
A list of the genes expressed at higher levels in GBM-associated astrocytes
when compared to low-grade-associated astrocytes. Genes are in order of the
difference of expression between GBM-associated and low grade-associated-
astrocytes. CD44 and TNC are each represented twice on the list. Osteopontin,
which is at the top of the list, is a ligand for the CD44 receptor.
doi:10.1371/journal.pone.0032453.t002
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[38,39] mice were also crossed onto the Ntv-a, Ink4a/Arf null
background to generate tumors that were heterozygous for Ink4a/
Arf and Olig2-rp-GFP. For human orthotopic tumors, 100,000
cells from human tumorsphere cultures [49] were injected into
host mice which were then monitored carefully for symptoms of
tumor development and sacrificed upon manifestation of these
symptoms. All animal work was conducted using protocols
approved by the Institutional Animal Care and Use Committee
at Memorial Sloan-Kettering Cancer Center. The approved
protocols are 00-11-189 (MSKCC, last approved 3/15/2010).
Cell Culture
DF1 cells overexpressing RCAS-PDGF, RCAS-PDGF-sv40-
GFP or RCAS-PDGF-mRFP were maintained in media contain-
ing 10% FBS in a humidified atmosphere containing 5% carbon
dioxide at 39 degrees. Neurosphere cultures were maintained in
basal media (Stem Cell Technologies) supplemented with 5%
Figure 3. Perivascular Astrocytes Can Be Stromal in Origin. A) Immunofluorescence for PDGF-GFP (green) and GFAP (red) in a PDGF-GFP-
driven glioma shows expression of PDGF-GFP and GFAP are mutually exclusive, indicating that TAAs are not derived from the tumor cell of origin.
Scale bars=100 mm. Inset, high-magnification images. Scale bars=10 mm. B) Immunofluorescence for GFAP (red) and GFP (green) in an orthotopic
model of human glioma. Human tumorspheres were injected into GFAP-GFP reporter mice such that tumor derived astrocytes will express GFAP but
not GFP and host/stromal astrocytes will co-express GFAP and GFP. While some astrocytes express only GFAP, many astrocytes also express GFP and
are thus derived from the host stromal environment. Expression of stromal GFAP-GFP occurs in all areas of GFAP immunoreactivity. Scale
bars=25 mm. Inset, high-magnification images. Scale bars=10 mm. C) FACS analysis of a PDGF-RFP-driven glioma in an Olig2-rp-GFP mouse, where
PDGF-infected tumor cells express RFP and Olig2-expressing cells express GFP. Most cells infected with the PDGF-RFP virus are Olig2-rp-GFP-
expressing cells. D) FACS analysis of a PDGF-RFP-driven glioma in a GFAP-GFP mouse, where PDGF-infected cells express RFP and astrocytes express
GFP. Most of the TAAs were not infected with RCAS-PDGF-RFP.
doi:10.1371/journal.pone.0032453.g003
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as previously described [50].
Immunohistochemistry and Immunofluorescence
For paraffin embedded samples, tumors were fixed in 10%
formalin and embedded in paraffin. Histological grading was
determined based on Hematoxylin and Eosin staining and the
presence of high-grade structures. DAB staining was performed
using the Ventana DAB-MAP system. The following antibodies
were used for DAB staining: GFAP (1:10,000, DAKO), CD44
(1:1000, BD Biosciences). Immunofluorescence was performed on
10% formalin fixed, paraffin embedded samples as well as on 4%
paraformaldehyde fixed tissues embedded in OCT and frozen. For
paraffin embedded tissue: tissues were deparaffinized and
rehydrated in graded alcohols. Antigen unmasking was performed
at 93u for 15 minutes. Tissues were then permeabilized in 0.3%
Figure 4. GBM Astrocyte-associated Stromal Genes Can Predict Survival in Human Proneural Glioma. A) Dot-plot of the expression
levels of all genes significantly expressed in whole tumor extracts (tumor plus stroma) versus Olig2-expressing tumor cells only. Red shaded area
demarcates genes expressed at a higher level in Olig2-expressing tumor cells, whereas blue shaded area demarcates genes expressed at a higher
level in Olig2-negative, stromal cells. Black dots represent genes identified as GBM TAAs signature genes. B) Analysis of the predictive value of the
GBM TAA genes. For each gene, patients were divided into high expressers and low expressers, based on whether their expression of the gene was
above or below the median. Kaplan Meier curves were then generated for the two groups and the difference in survival between low and high
expressers was plotted. Black dots indicate a non-significant difference in survival and colored dots indicate a significant difference in survival, where
red is *** (p,0.001), blue is ** (p,0.01), and green is * (p,0.05).
doi:10.1371/journal.pone.0032453.g004
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primary antibody. The next morning, samples were washed in
0.1% triton-X/PBS and stained in the appropriate alexa-fluor
tagged secondary antibody for 2 hours at room temperature.
Samples were then counterstained with DAPI and mounted in
70% glycerol or prolong gold (Invitrogen). For frozen samples:
tissues were air-dried and then permeabilized, blocked and stained
as described above. The following antibodies were used for
fluorescent staining: GFAP (1:2000, Dako), CD44 (1:1000, BD
Pharmingen), MHCII (212-A1 antibody, 1:1000, a gift from Dr,
Lisa Denzin), IBA-1 (1:500 Wako), Nestin (1:100, BD Pharmingen)
Tenascin C (1:100, Abcam).
FACS Sorting/Analysis
For analysis and sorting of tumors, tumors were enzymatically
digested in EBSS containing 12% papain (Worthington) and
10 mg/ml DNase at 37uC for 15 minutes. The digestion was
stopped with 1 mg/ml ovomucoid (Worthington). Cells were
washed and resuspended in basal medium and sorted using a
Cytomation MoFlo cell sorter. Cells to be used on the array were
collected in PBS, centrifuged and resuspended in trizol. Cells that
were to be cultured were collected directly into the appropriate
media. For analysis and sorting of primary neurospheres, spheres
were mechanically dissociated, resuspended in basal media and
sorted using a Beckton-Dickinson FACSCalibur flow cytometer.
Antibodies used for FACS include CD44-PE (1:100, BD
Pharmingen), CD44-Pacific blue (1:100, Biolegend), APC-conju-
gated MHC-II (1:500, ebiosciences), CD45-APC (1:100, BD
Pharmingen), CD31-APC (1:100, BD Pharmingen).
Array
GFAP-GFP-expressing astrocytes were collected by FACS from
Ink4a/Arf heterozygous mice with or without PDGF-driven
gliomas. Prior to sorting, a piece of the tumor was removed for
histological analysis of grade. Six samples each of Normal, low-
grade-associated and GBM-associated astrocytes were collected,
pelleted and then resuspended in trizol. Three samples of Olig2-
rpGFP cells and three samples of whole tumors were resuspended
in trizol. RNA was extracted from normal astrocytes as well as
from samples enriched for TAAs and Illumina-6 arrays were run
by the genomics core at MSKCC. For the Olig2-rpGFP versus
whole tumor array, Illumina-8 arrays were used. Array data was
analyzed using Partek analysis software. Data was imported as a
text file and was quantile and then log2 normalized prior to
analysis. ANOVA statistics were run to determine significantly
changed genes. Gene lists were uploaded into Ingenuity Pathway
Analysis for analysis of relevant pathways.
Analysis of Human Data
Expression values for each gene of interest were obtained from
the MSKCC computational biology cancer genomics portal,
http://www.cbioportal.org/cgx/index.do, which has annotated
TCGA data. Patient survival data was obtained from published
TCGA information [6]. For each subtype of tumors, the mean and
median expression for each GBM TAAs gene was determined.
Patients were then divided into two groups (‘high’ and ‘low’),
depending on whether their expression of the gene was above or
below the median, and Kaplan Meier curves were generated
based on the resulting data. The difference in survival between
patients with high expression of a given gene compared to patients
with low expression of that gene was then calculated for each gene
in each subtype and that difference in survival was plotted on a
new graph.
Statistical Analysis
Array statistics were performed using ANOVA in the Partek
analysis software. Comparison of the changes in MHC-II
expression in astrocytes and CD44 expression in differentiated
and neurosphere conditions, as well as the differences in gene
expression between subtypes was performed using a two-tailed t-
test in prism software.
Supporting Information
Figure S1 Astrocytes in Glioma. A) Examples of Low-grade
Gliomas and GBMs at low- and high-magnification. B) Immuno-
fluorescence of tumors from Lectin-GFP injected mice stained
with GFAP (red) demonstrates that astrocytes within the tumor
reside close to blood vessels. Scale bars=10 mm.
(TIF)
Figure S2 Gfap-GFP Reporter Recapitulates Endoge-
nous GFAP Expression. A) Immunofluorescence for GFAP
(red) and GFP (green) in the hippocampus of a normal brain from
a GFAP-GFP mouse shows colocalization of the GFP reporter
with GFAP protein. Scale bars=50 mm. B) Immunofluorescence
for GFAP (red) and GFP (green) in a tumor-bearing brain shows
colocalization of the GFP reporter with GFAP protein. Scale
bars=10 mm C) FACS analysis indicates that GFAP-GFP cells do
not colocalize with CD31-expressing endothelial cells. GFAP-GFP
expression is on the x-axis; CD31 expression is on the y-axis. D)
FACS analysis indicates that GFAP-GFP cells do not colocalize
with CD45-expressing immune cells. GFAP-GFP expression is on
the x-axis; CD45 expression is on the y-axis.
(TIF)
Figure S3 MHC Class II Expression is Increased in
Tumor-associated Astrocytes When Compared to Normal
Astrocytes. A) Immunofluorescence for MHC II (red), GFAP
(green) and Iba-1 (white) in low grade- and GBM-associated
astrocytes shows co-localization of MHC II with GFAP-expressing
astrocytes. Arrowheads point to MHC II-expressing astrocytes that
are Iba-1 negative and thus not immune cells. Scale bars=10 mmB )
FACS analysis of normal and tumor-bearing brains for expression of
MHC class II (y-axis) and GFAP-GFP (x-axis). In normal brains,
there is very little MHC II expression and virtually no expression on
astrocytes. However, ina tumor-bearing brain, MHCII expression is
increased in the tumor and specifically within the astrocyte
population. C) Quantification of results of FACS analysis: in a
normal brain, approximately1.5% ofastrocytes express MHCII and
in a tumor brain, approximately 17.5% of astrocytes express
MHCII, p=0.0351.
(TIF)
Figure S4 CD44 Expression in Astrocytes. A) Immunoflu-
orescent staining for CD44 (red) and GFAP (green) in the sub-
ventricular zone of a normal brain. Arrows point to CD44-
expressing astrocytes near the ventricle (V). In addition to
expressing CD44, these astrocytes have a bipolar morphology,
which is a hallmark of adult astrocyte-like stem cells [24].
Arrowheads point to CD44-negative astrocytes further from the
ventricle.In additionto being far from the ventricle, these astrocytes
haveprocessesextendinginmultipledirections,indicatingthatthese
cells are not adult astrocyte-like stem cells [24]. Scale bars=10 mm.
B) FACS analysis of tumors cultured in serum-containing media or
neurosphere media demonstrates that CD44 expression is only
maintained in neurosphere conditions. Also, when normal astro-
cytes are cultured as neurospheres they express CD44. CD44
expression is on the x-axis and GFAP-GFP expression is on the y-
axis. C) Quantification of FACS data. After one week, approxi-
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CD44. D) Host-derived, murine GFAP-GFP-expressing astrocytes
from an orthotopic model of human glioma were sorted, collected
andgrownasneurospheres.Withintheseculturesthereissignificant
expression of GFAP-GFP, indicating the ability of stromal
astrocytes to grow as neurospheres. Scale bars=100 mm.
(TIF)
Figure S5 GBM TAAs Genes can Predict Survival in
Human Proneural Glioma. Representative Kaplan Meier curves
for the GBM TAAs genes in each subtype as well as G-CIMP only
t u m o r s .B l u el i n er e p r e s e n t ss u r v i v a l of patients with expression below
the median for each gene in each subtype and black line represent
survival for patients with expression above the median for each gene
in each subtype, *=p,0.05, **=p,0.01, ***=p,0.001. Survival is
represented in months to death after diagnosis.
(TIF)
Figure S6 G-CIMP Patients Have Lower Expression of
GBM TAAs Genes. Plot of average expression of the GBM
TAAs signature genes in each subtype and in proneural G-CIMP
and non-G-CIMP patients. The average expression for all GBM
TAAs genes was lowest in the proneural subtype and lower in
proneural G-CIMP patients when compared to proneural non-G-
CIMP patients. *=p,0.05, **=p,0.01, ***=p,0.001.
(TIF)
Table S1 MHC Class II Pathway is increased in Tumor-
associated Astrocytes Relative to Normal Astrocytes. List
of MHC Class II pathway genes that are increased in TAAs
compared to normal astrocytes. Values listed as fold change in
expression when TAAs were compared to normal astrocytes.
(TXT)
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